Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
Background: Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier España
2021-01-01
|
| Series: | Pulmonology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531043720301537 |